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Abstract
Background: Previous studies identified melatonin receptor 1B (MTNR1B), islet-specific glucose 6 phosphatase catalytic
subunit-related protein (G6PC2), glucokinase (GCK) and glucokinase regulatory protein (GCKR) as candidate genes for type 2
diabetes (T2D) acting through elevated fasting plasma glucose (FPG). We examined the associations of the reported
common variants of these genes with T2D and glucose homeostasis in three independent Chinese cohorts.
Methodology/Principal Findings: Five single nucleotide polymorphisms (SNPs), MTNR1B rs10830963, G6PC2 rs16856187
and rs478333, GCK rs1799884 and GCKR rs780094, were genotyped in 1644 controls (583 adults and 1061 adolescents) and
1342 T2D patients. The G-allele of MTNR1B rs10830963 and the C-alleles of both G6PC2 rs16856187 and rs478333 were
associated with higher FPG (0.0034,P,6.6610
25) in healthy controls. In addition to our previous report for association with
FPG, the A-allele of GCK rs1799884 was also associated with reduced homeostasis model assessment of beta-cell function
(HOMA-B) (P=0.0015). Together with GCKR rs780094, the risk alleles of these SNPs exhibited dosage effect in their
associations with increased FPG (P=2.9610
29) and reduced HOMA-B (P=1.1610
23). Meta-analyses strongly supported
additive effects of MTNR1B rs10830963 and G6PC2 rs16856187 on FPG.
Conclusions/Significance: Common variants of MTNR1B, G6PC2 and GCK are associated with elevated FPG and impaired
insulin secretion, both individually and jointly, suggesting that these risk alleles may precipitate or perpetuate
hyperglycemia in predisposed individuals.
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Introduction
Elevated fasting plasma glucose (FPG) level is an important risk
factor contributing to cardiometabolic diseases. Impaired fasting
glucose, defined as FPGfrom 5.6 to 6.9 mmol/l (ADA criteria) [1] or
6.1 to 6.9 mmol/l (WHO criteria) [2], is associated with increased
risk of diabetes and cardiovascular disease [3,4]. Adequate insulin
secretion and sensitivity is critical in the maintenance of euglycemia
[5]. FPG level is shown to be moderately heritable in twin and family
studies (heritability estimate h
2=0.20–0.28 [6,7,8]. Recent genome-
wide association studies (GWAS)haveuncovered afew loci associated
with FPG, including genes encoded for melatonin receptor 1B
(MTNR1B), glucose-6-phospate catalytic subunit 2 (G6PC2),
glucokinase (GCK) and glucokinase regulatory protein (GCKR)
[9]. Surprisingly, these genes only demonstrated modest or weak
association with type 2 diabetes (T2D) [9,10,11], despite a close
interplay between T2D and high FPG level. Although most T2D
genes are implicated in beta-cell function [12], high FPG level from
other causes can worsen insulin secretion or sensitivity by setting up a
vicious cycle via glucotoxicity [13].
MTNR1B, GCK and G6PC2 proteins are expressed in the
human beta cells [14,15,16]. MTNR1B encodes a high affinity
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pineal gland to regulate circadian rhythm and sleep cycles [17].
Plasma melatonin follows an opposite circadian rhythm to plasma
insulin and glucose, rising by night and falling by day, which
suggests that melatonin may affect insulin release and glucose level
via its islet-specific receptor [18]. Large scale association studies
[9,10,14] suggested that two common MTNR1B SNPs rs1387153
and rs10830963 (r
2=0.7 in Europeans) may affect insulin
secretion and glucose homeostasis.
Glucokinase (encoded by GCK) is a glucose-sensing enzyme that
determines the threshold for glucose-stimulated-insulin-secretion
(GSIS) in islets, and controls gluconeogenesis and glycogen
synthesis in hepatocytes [15]. The hepatic activity of GCK is
inhibited by its regulatory protein GCKR in a dose-dependent
manner, which competes with glucose for binding site [19]. Two
GCKR variants rs780094 and rs1260326 (r
2=0.93 in Europeans)
are associated with HOMA-IR, FPG and triglyceride levels
[20,21]. A functional study showed that this effect was mediated
through reduced repression on GCK [22].
The GCK variant rs1799884 is associated with higher FPG in
Caucasian and Chinese cohorts [23,24,25], and rare GCK
mutations confer a form of maturity-onset diabetes of the young
(MODY 2) characterized by hyperglycemia [26]. Glucose-6-
phospate catalytic subunit 2 (encoded by G6PC2) is proposed to
counteract pancreatic GCK activity by competing for glucose
usage [16]. G6PC2-null mice demonstrated a ,15% reduction in
FPG level [27], and two SNPs rs560887 and rs563694 were
repeatedly associated with hyperglycemia in Europeans
[10,28,29,30]. However, these two variants are nearly monomor-
phic in Asians, so Hu et al. adopted a tagSNP approach and
reported a FPG-associated SNP rs16856187 in Chinese [31].
Based on their common effects on FPG levels and co-presence
in the beta-cell and liver, variants in MTNR1B, GCK, G6PC2 and
GCKR are hypothesized to have interactions or joint effects.
Bouatia-Naji et al. have reported their additive effects on FPG
[9,32], and we have previously shown that a variant in GCKR
modifies the association between GCK and FPG [24]. In this study,
we aimed to validate the reported dosage effects on FPG in a
Chinese cohort, and examined their associations with insulin
secretion and sensitivity as estimated by HOMA-IR and HOMA-
B indices.
Materials and Methods
Subjects
We have previously described the study design, ascertainment,
inclusion criteria and phenotyping procedures of subjects included
in this study [33]. All subjects were of southern Han Chinese
ancestry residing in Hong Kong. The control cohort consists of
1644 subjects with FPG,6.1 mmol/l ascertained from a) 583
hospital staff and volunteers from a community-based health
screening program (mean age 41.4610.5 years, 45% male) and b)
1061 adolescents from a community-based school survey (mean
age 15.461.9 years, 45% male). A subgroup of 420 adult controls
also underwent a 75g oral glucose tolerance test (OGTT). The
case cohort consists of 1342 unrelated T2D patients (mean age
50.5613.7 years, 41% male, mean duration of T2D 6.166.5
years) selected from the Hong Kong Diabetes Registry (HKDR).
T2D was diagnosed according to the 1998 World Health
Organization (WHO) criteria. Patients with classic type 1 diabetes
with acute ketotic presentation or continuous requirement of
insulin within 1 year of diagnosis were excluded. The clinical
characteristics of subjects in the three cohorts are summarized in
Table 1. Written informed consent was obtained from all adult
subjects and parents of the adolescents while the adolescents gave
verbal consent. This study was approved by the Clinical Research
Ethics Committee of the Chinese University of Hong Kong.
Clinical studies
All study subjects were examined in the morning after an
overnight fast. Anthropometric measurements including body
weight and height were documented. Fasting blood samples were
collected for DNA extraction and measurements of FPG and fasting
plasma insulin (FPI). Homeostasis model assessment of insulin
resistance (HOMA-IR) was calculated as (FPI6FPG)722.5, and
homeostasis model assessment of beta-cell function (HOMA-B) was
calculated as FPI6207(FPG - 3.5) [34]. Insulinogenic index was
calculated as (PI during OGTT for 30 min - 0 min)7(PG during
OGTT for 30 min - 0 min) [35]. Data were discarded if PI or PG
level at 0 min were higher than that of 30 min. Insulin sensitivity
index (ISI) was estimated using the formula proposed by Matsuda
and DeFronzo [36]: 10,0007[FPG6FPI6(mean PG during
OGTT)6(mean PI during OGTT)]
1=2. Insulin disposition index
(IDI) was calculated as ISI6insulinogenic index7100 [36].
Genotyping
We genotyped five SNPs in four genes including MTNR1B
rs10830963, G6PC2 rs16856187 and rs478333, GCK rs1799884
and GCKR rs780094 in all study subjects due to their reported
associations with FPG, beta-cell function and T2D [29,31,32],
except for G6PC2 rs478333. Although G6PC2 rs560887 [28,30]
and G6PC2 rs563694 [29] showed association with FPG in
Caucasian populations, both of their corresponding minor allele
frequencies (MAF) are rare in Chinese population (0.006 and
0.012 in HapMap CHB for rs560887 and rs563694, respectively).
Table 1. Clinical and metabolic characteristics of 1644 healthy Chinese adults and adolescents and 1342 T2D patients.
Characteristics Healthy Adults Healthy Adolescents T2D Patients
N (male/female) 583 (265/318) 1061 (481/580) 1342 (544/798)
Age (years) 41.4610.5 15.461.9 50.5613.7
Age-at-diagnosis (year) – – 44.5613.7
Disease duration (years) – – 6.166.5
Body mass index (kg/m
2) 22.963.3 19.963.5 25.064.0
Fasting plasma glucose (mmol/l) 4.860.4 4.760.3 –
Fasting plasma insulin (pmol/l) 40.8 (25.9–58.6) 45.0 (35.4–60.2) –
Data are shown as N, mean 6 SD or median (interquartile range).
doi:10.1371/journal.pone.0011428.t001
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the strongest signal for both T2D and FPG. To clarify these inter-
ethnic differences, we genotyped rs16856187 and another nearby
SNP rs478333 located in the 39 flanking region, which has
common allele frequencies in both Chinese (0.29 in HapMap
CHB) and Caucasian (0.49 in HapMap CEU) populations. We did
not test for associations for all tagging SNPs of the respective
genes. Genotyping on genomic DNA was performed either at
deCODE Genetics using the Centaurus (Nanogen) platform or at
the McGill University and Genome Quebec Innovation Centre
using the Sequenom MassARRAY platform (San Diego, CA,
USA). The concordance rate for part of the samples genotyped on
both platforms is .99%. All SNPs were in Hardy-Weinberg
equilibrium (P.0.05) in control cohorts using the exact test
implemented in PLINK [37]. The overall genotype call rates were
.96% and the minor allele frequencies (MAF) in normal controls
(MAF of MTNR1B rs10830963=0.44 for both adult and
adolescent controls; G6PC2 rs16856187 and rs478333=0.30 and
0.35, respectively for both adult and adolescent controls; GCK
rs1799884=0.16 and 0.19 in adult and adolescent controls,
respectively) were comparable with the HapMap CHB data (0.48
for MTNR1B rs10830963; 0.28 and 0.29 for G6PC2 rs16856187
and rs478333, respectively; 0.20 for GCK rs1799884), except the
one of GCKR rs780094. MAFs of GCKR rs780094 in our data (0.46
for both adult and adolescent cohorts) were lower than seen in the
HapMap CHB (0.60), but they were similar to the frequency
reported in a group of Han Chinese (0.44) study [21].
Systematic Review
A systematic literature search was performed according to the
MOOSE guidelines [38] for the meta-analysis of observational
studies. The description of studies and details of the literature
search process are outlined in the table (Table S1) and the flow
chart (Figure S1), respectively. We searched the PubMed database
from inception to January 2010 for association studies between
fasting glucose and MTNR1B or G6PC2 genes. The keywords used
were MTNR1B, G6PC2 and fasting glucose. We restricted our
analysis to human studies, and placed no language restriction. We
included studies if they (a) reported the association results for
subjects in case-control or population-based studies; (b) genotyped
MTNR1B rs10830963, G6PC2 rs560887 or rs16856187 and
measured fasting glucose levels for the studied subjects; (c)
presented results as mean 6 SD with sample size stratified by
genotypes with or without adjustment for covariate. We excluded
studies if they (a) were reviews or abstract; (b) were duplicate
reports on previously published studies; (c) did not provide
sufficient information for computation of a quantitative effect
estimate of the relationship between FPG and genetic variants.
Statistical analysis
All data are presented as percentage, mean 6 SD or median
(interquartile range), as appropriate. Insulinogenic index, FPI,
HOMA-IR, HOMA-B, ISI and IDI were logarithmically
transformed due to skewed distributions. Each trait was winsorized
separately in adult and adolescent cohorts by replacing extreme
values with 4 standard deviations from the mean. Less than 0.2%
of data were replaced.
Within each control cohort, associations between genotypes and
phenotypic traits were tested by multivariate linear regression
adjusted for sex, age, and BMI (where appropriate) under the
additive genetic model. In the combined analysis, an additional
dummy variable ‘‘study cohort’’ coded as 0 for adult controls and
1 for adolescent controls was included in the regression model.
Multiple testing of phenotypic traits and SNPs were corrected by
controlling the false discovery rate (FDR) using the Benjamini-
Hochberg approach [39]. An alternative method for controlling
multiple testing is developed by Conneely and Boehnke [40],
which accounts for correlation both among SNPs and among
phenotypes and is less conservative than FDR. To assess gene-
gene interaction effects on phenotypic traits, linear regression
analyses including the main and pairwise interaction effects of
SNPs under an additive genetic model were applied. The joint
effects of the SNPs was assessed by calculating the estimated
marginal mean with 95% confidence intervals (CIs) in a general
linear model (including sex, age, BMI and study cohort as
covariates), categorized by the number of risk alleles assuming an
additive genetic model. Risk alleles were defined as alleles that
increased fasting plasma glucose described either in literature or in
the present study. The significance of the trend was tested by linear
regression using the number of risk alleles carried as an
independent variable.
Frequencies of genotypes and number of risk alleles between
T2D cases and healthy controls were compared using logistic
regression adjusted for age, sex and BMI. Odd ratios (ORs) with
95% CIs were presented.
Meta-analyses for the association of FPG were calculated based
on the Hedges g statistic which was used to calculate the
standardized mean difference (SMD) across studies under the
fixed effects model. To account for heterogeneity of SMDs across
studies (Cochran’s Q statistic P,0.1), the overall effect size (SMD)
under the random effects model was reported, in which both
random variations within and between different studies were
incorporated [41].
We estimated study power using genetic power calculator [42].
Assuming an additive model with the frequencies of 0.41 [43] for
the G-allele of MTNR1B rs10830963, 0.30 [31] for the C-alleles of
G6PC2 rs16856187, 0.17 [24] for the A-allele of GCK rs1799884
and 0.54 [24] for the C-allele GCKR rs780094 in a Chinese
population, our sample size has .90% power to detect a T2D risk
under the prevalence of 0.1 with an odds ratio of 1.16 [43], 1.19
[31], 1.22 [25] and 1.18 [21] respectively, and a per-allele effect of
increasing FPG by .0.068 (total QTL variance=0.012) and
.0.067 (total QTL variance=0.012) mmol/l [31,43] for
rs10830963 and rs16856187 respectively, at the a level of 0.05.
All statistical analyses were performed using SAS v.9.1 (SAS
Institute, Cary, NC, USA) or SPSS for Windows v.15 (SPSS,
Chicago, IL, USA) unless specified otherwise. Two-tailed P values
,0.05 were considered statistically significant.
Results
Associations with FPG, beta cell function and T2D
We have previously shown that the minor A-allele of GCK
rs1799884 was associated with higher FPG, nevertheless, no
association was detected for GCKR rs780049. In this study, we
further observed consistent and significant association of the minor
G-allele of MTNR1B rs10830963 (Beta6S.E.=0.03760.012 and
P=0.0034 in combined analysis) as well as the C-alleles of both
G6PC2 rs16856187 (Beta6S.E.=0.05960.015 and P=6.6610
25
in combined analysis) and rs478333 (Beta6S.E.=0.05060.013
and P=0.0002 in combined analysis) with increased FPG after
adjustment for age, gender, BMI and/or study cohorts (Table 2
and 3).
In addition, association with reduced beta-cell function as
assessed by HOMA-B was also observed for the A-allele of GCK
rs1799884 (Beta6S.E.=20.08160.026 and P=0.0015), as well
as trend for associations with the G-allele of MTNR1B rs10830963
(Beta6S.E.=20.03760.019 and P=0.0532) and the C-allele of
Chinese Fasting Glucose Genes
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the combined control samples (Tables 2, 3, 4).
The associations of FPG with MTNR1B rs10830963
(P=0.0162), G6PC2 rs16856187 (P=0.0013) and rs478333
(P=0.0019), as well as GCK rs1799884 with HOMA-B
(P=0.0095) in the combined control samples remained signifi-
cant after controlling for FDR. None of the SNPs revealed
association with T2D (Table S2), BMI, FPI or insulin sensitivity,
as measured by HOMA-IR (Tables 2, 3, 4) or OGTT-based traits
(Table S3).
Table 2. Associations of MTNR1B rs10830963 with type 2 diabetes related traits in Chinese control subjects.
Study Genotypes n BMI (kg/m
2) FPG (mmol/l) FPI (pmol/l) HOMA-IR HOMA-B
Adults CC 181 2363.4 4.7960.42 36.0 (23.2–55.9) 1.3 (0.9–2.0) 96.7 (61.6–161.7)
CG 286 2363.2 4.8460.41 44.8 (29.9–60.9) 1.6 (1.0–2.2) 111.8 (75.8–170.9)
GG 116 22.363.2 4.9160.42 37.3 (24.1–55.8) 1.4 (0.9–2.0) 88.0 (56.8–130.3)
P 0.1268 0.0069 0.2271 0.1234 0.8931
Adolescents CC 342 19.963.5 4.7060.35 47.8 (35.5–64.1) 1.6 (1.2–2.3) 140.1 (100.4–191.3)
CG 503 19.863.4 4.7660.33 43.9 (35.0–58.7) 1.6 (1.2–2.1) 124 (94.0–162.6)
GG 216 20.263.7 4.7460.33 44.9 (36.1–59.5) 1.6 (1.2–2.1) 124.7 (99.1–168.1)
P 0.4961 0.0475 0.2251 0.4303 0.0042
Combined P 0.8903 0.0034 0.9901 0.6471 0.0532
Adjusted P 0.9901 0.0162 0.9901 0.8785 0.1685
Data are expressed as N, mean 6 SD or median (interquartile range). P values were calculated from linear regression adjusted for sex, age and BMI (where appropriate)
assuming an additive genetic model. In the combined analysis, calculated P values were also adjusted for study cohorts (adult or adolescent). Adjusted P values refer to
the P values controlled for false discovery rate in combined analysis. BMI, body mass index; FPG, fasting plasma glucose; FPI, fasting plasma insulin; HOMA-IR, HOMA of
insulin sensitivity; HOMA-B, HOMA of beta- cell function.
doi:10.1371/journal.pone.0011428.t002
Table 3. Associations of G6PC2 rs16856187 and rs478333 with type 2 diabetes related traits in Chinese control subjects.
Study Genotypes n BMI (kg/m
2) FPG (mmol/l) FPI (pmol/l) HOMA-IR HOMA-B
rs16856187
Adults AA 262 22.963.4 4.8060.41 41.0 (25.9–56.7) 1.5 (0.9–2.0) 104.4 (70.3–162.2)
AC 245 22.763.0 4.8860.43 40.5 (26.4–58.9) 1.5 (1.0–2.1) 104.7 (62.9–161.7)
CC 45 23.663.7 4.9160.35 43.0 (25.9–65.2) 1.5 (0.9–2.4) 110.0 (71.8–184.9)
P 0.9415 0.0428 0.3096 0.2079 0.9689
Adolescents AA 454 20.063.7 4.6960.33 45.1 (35.0–62.3) 1.6 (1.2–2.2) 133.4 (100.2–178.8)
AC 414 19.963.3 4.7760.35 44.8 (35.7–59.7) 1.6 (1.2–2.1) 125.5 (92.4–164.2)
CC 75 19.863.6 4.7860.30 47.5 (35.7–60.0) 1.7 (1.3–2.1) 125.2 (95.1–168.8)
P 0.5112 8.5610
25 0.7023 0.2428 0.0252
Combined P 0.6473 6.6610
25 0.4416 0.1720 0.1336
Adjusted P 0.8785 0.0013 0.7997 0.1685 0.3173
rs478333
Adults TT 238 22.963.3 4.7960.40 41.2 (25.4–60.3) 1.5 (0.9–2.1) 111.3 (67.7–173.7)
TC 260 22.863.1 4.8860.43 40.0 (25.9–56.8) 1.5 (1.0–2.1) 103.5 (62.5–151.0)
CC 71 23.063.7 4.8760.42 40.7 (27.2–60.7) 1.5 (0.9–2.2) 100.2 (72.3–160.1)
P 0.9930 0.0561 0.5608 0.4078 0.8290
Adolescents TT 437 19.963.5 4.7060.33 44.5 (35.2–63.6) 1.5 (1.2–2.2) 134.2 (102.0–182)
TC 477 20.063.4 4.7560.34 46.3 (35.7–59.5) 1.6 (1.2–2.1) 127.5 (93.9–168.1)
CC 123 19.863.3 4.8060.33 44.7 (35.2–57.5) 1.6 (1.2–2.0) 114.6 (94.2–158.7)
P 0.9054 0.0008 0.7888 0.7341 0.0068
Combined P 0.9845 0.0002 0.9287 0.5535 0.0623
Adjusted P 0.9901 0.0019 0.9901 0.8764 0.1691
Data are expressed as N, mean 6 SD or median (interquartile range). P values were calculated from linear regression adjusted for sex, age and BMI (where appropriate)
assuming an additive genetic model. In the combined analysis, calculated P values were also adjusted for study cohorts (adult or adolescent). Adjusted P values refer to
the P values controlled for false discovery rate in combined analysis. BMI, body mass index; FPG, fasting plasma glucose; FPI, fasting plasma insulin; HOMA-IR, HOMA of
insulin sensitivity; HOMA-B, HOMA of beta- cell function.
doi:10.1371/journal.pone.0011428.t003
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function and T2D
We did not detect any novel pairwise interaction between genes on
FPG level or beta-cell function in the combined healthy controls (data
not shown), apart from the one previously reported between GCK
rs1799884 and GCKR rs780094. We then examined the joint effects of
selected SNPs from GCK,GCKR,MTNR1B,G6PC2 genes on FPG and
beta-cell function, assuming that all risk alleles have similar effect sizes.
Due to the relatively high linkage disequilibrium between G6PC2
rs16856187 and G6PC2 rs478333 (r
2=0 . 6 2i nb o t hH a p M a pC H B
dataand the present study), only themostsignificant SNP was included
for the joint analysis of FPG or beta-cell function, respectively. We
tested for the independence between loci by using all four
corresponding loci in the regression models. All loci were independent
(P,0.05) except for GCKR rs780094. Subjects with increasing number
of risk alleles showed higher FPG concentration (P=2.9 610
29)a n d
lower value of HOMA-B (P=1.1 610
23) (Figure 1A–B) in a dose-
dependent manner. In addition, we did not find any association
b e t w e e nT 2 Da n dc o m b i n e dg e n ev a r i a n t s( T a b l eS 2 ) .
Meta-analyses of MTNR1B rs10830963 and G6PC2
rs16856187 with FPG
In our previous study, we have confirmed the association of
GCK rs1799884 with FPG in a meta-analysis including both
Europeans and Chinese populations. In the present study, meta-
analysis of association of MTNR1B (rs10830963) in Europeans
showed increases of 0.15 (0.11–0.19) and 0.29 (0.25–0.34) in
(SMD) of FPG for CG and GG genotypes, respectively, when
compared to the CC reference genotype (Figure S2). However,
weaker and dominance effect was found in Chinese, with increases
of 0.20 (0.11–0.28) and 0.23 (0.12–0.34) in SMD of FPG for CG
and GG genotypes, respectively (Figure S2). In the combined
meta-analysis for all European and Chinese cohorts, we confirmed
the additive effect of the G-allele in MTNR1B rs10830963 with
FPG. Furthermore, an additive trend of 0.15 (0.03–0.27) and 0.31
(0.19–0.44) increases in SMD of FPG for AC and CC genotypes,
respectively, when compared to the AA reference genotype, was
also observed for G6PC2 rs16856187 in Chinese populations
(Figure S3). Due to significant heterogeneity amongst the study
cohorts (P,0.1), the combined SMDs were calculated based on
the random effect models, only using the fixed effect models for the
association of MTNR1B rs10830963 in all Chinese cohorts (P.0.1)
(Figure S3).
Discussion
Here we reported the association of rs10830963 in MTNR1B,
rs16856187 and rs478333 in G6PC2, and rs1799884 in GCK with
higher FPG and lower HOMA-B levels. Further analyses of the
risk alleles (G-allele of rs10830963, C-alleles of both rs16856187
and rs478333, A-allele of rs1799884 and C-allele of GCKR
rs780094) confirmed their joint effects on FPG and beta-cell
function. These consistent findings from three independent
cohorts strongly support the risk effects of these variants on GSIS
to predispose hyperglycemia in Chinese.
Consistent with previous studies [9,10,28,30,32,44,45,46,47],
we observed the individual and joint effects of risk alleles in
MTNR1B, G6PC2, and GCK on FPG. Compared to the carriers
with 0 or 1 alleles, each additional allele increases mean FPG level
by 0.048 (0.032–0.064) mmol/l (Figure 1). This effect size is similar
to those observed in Dutch (0.05 (0.04–0.07)) [32], French (0.07
(0.06–0.08) [9], and Japanese (0.055 (0.045–0.065)) [45] popula-
tions, despite the use of different risk variants. While GCK
rs1799884 and MTNR1B rs10830963 are strongly associated to
FPG in both Caucasian and Asian cohorts [21,43,45,48], we and
others have observed an Asian specific G6PC2 risk variant
(rs16856187 in Hu et al [31] and the current study, and
rs3755157 in Takeuchi et al [45], r
2$0.9) in addition to the
Caucasian reported rs563694 (Figure S4). This suggests that while
these loci are reproducibly associated to FPG across populations,
as shown in our meta-analyses (Figures S2, S3), replication in
multiple ethnicities could help to identify population specific risk
variants and filter for causal variants. Since G6PC2 rs478333 is
common in both Asian (0.29 in Hapmap CHB) and Caucasian
(0.49 in HapMap CEU), its replication could provide new insight.
Together, the Asian-specific rs16856187 and rs478333 and the
Caucasian specific rs563694 (r
2=0.02 and 0.03 to rs16856187
and rs47833, respectively) helped refined a 8.8 kb region of
interest (Figure S4), which would be useful for future functional
studies.
We further observed that these variants exerted individual and
combined effects on beta-cell function, as estimated by the
homeostasis model (HOMA-B). To our knowledge, this is the first
study showing that the same risk alleles can jointly impair insulin
secretion and elevate FPG level. Each allele decreases mean
HOMA-B level by 0.04%, which may partially explain the
concomitant increase of 0.048 mmol/l in mean FPG level
(Figure 1). A recent GWAS meta-analysis involving ,100,000
Table 4. Associations of GCK rs1799884 and GCKR rs780094
with type 2 diabetes related traits in Chinese control subjects.
Study Genotypes n HOMA-IR HOMA-B
GCK rs1799884
Adults GG 399 1.5 (0.9–2.1) 106.4 (66.4–167.8)
GA 149 1.6 (1.0–2.2) 104.9 (62.8–161.7)
AA 16 1.4 (0.9–2.4) 102.5 (69.2–132.4)
P 0.6334 0.1551
Adolescents GG 686 1.6 (1.2–2.2) 133.7 (100.4–
178.2)
GA 303 1.6 (1.2–2.1) 119.5 (90.6–159.4)
AA 42 1.6 (1.2–2.0) 124.2 (88.0–170.2)
P 0.5414 0.0014
Combined P 0.8239 0.0015
Adjusted P 0.9901 0.0095
GCKR rs780094
Adults TT 123 1.5 (0.9–2.0) 108.9 (67.7–160.1)
TC 272 1.4 (0.9–2.0) 95.2 (62.2–155.8)
CC 169 1.5 (1.0–2.4) 112.8 (74.4–183.4)
P 0.3560 0.4322
Adolescents TT 192 1.6 (1.2–2.1) 128.7 (96.3–181.1)
TC 441 1.6 (1.2–2.1) 130.1 (97.6–168.2)
CC 273 1.7 (1.2–2.3) 130.3 (95.1–172.9)
P 0.2892 0.9381
Combined P 0.1503 0.4630
Adjusted P 0.3173 0.7997
Data are expressed asN, mean 6 SD or median (interquartile range). P values were
calculatedfromlinearregressionadjustedforsex,ageandBMI (whereappropriate)
assuming an additive genetic model. In the combined analysis, calculated P values
were also adjusted for study cohorts (adult or adolescent). Adjusted P values refer
to the P values controlled for false discovery rate in combined analysis. HOMA-IR,
HOMA of insulin sensitivity; HOMA-B, HOMA of beta- cell function.
doi:10.1371/journal.pone.0011428.t004
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G6PC2, and GCK were associated to FPG and HOMA-B at
genome-wide significant levels [48]. Most of the 17 FPG-
associated loci were also consistently associated to HOMA-B
[48]. Our result and other literature support that impaired beta-
cell function and hyperglycemia likely share the same underlying
pathogenic mechanism.
Although we had sufficient power (.90%) to detect T2D risks
with odds ratio ranging from 1.16 to 1.22 [21,25,31,43], we did
not detect T2D-associations for these four loci (P=0.47–0.88).
Several large-scale studies failed to find T2D-associations as well
[28,29], and even if found, their effects on T2D are shown to be
much weaker than their effects on FPG [9,10,11,21,31,32,43].
Dupuis et al. estimated that MTNR1B, GCK and GCKR were
associated to T2D with modest effect sizes of 1.06–1.09 [48], so
our result may be explained by a lack of power due to the small
sample size.
In pancreatic islets, glucose is phosphorylated by GCK into
glucose-6-phosphate (G6P), committing it for glycolysis and the
subsequent glucose-stimulated insulin secretion (GSIS). G6PC2 is
hypothesized to counteract this process, which removes the
phosphate group and releases glucose from the beta-cell [16].
MTNR1B may down regulate GCK expression and GSIS by
lowering intracellular cAMP level [17,49]. Indeed, GCK, G6PC2
and MTNR1B knock out mice demonstrated significantly lower
FPG levels [18,27,50]. Thus, the coexistences of risk alleles in
MTNR1B, G6PC2, and GCK may confer high melatonin level, low
intra-islet glucose oxidation, and low GCK activity in carriers,
causing decreased insulin secretion and increased FPG level as
observed in this study. The low number of overlapping loci
between FPG and T2D GWAS studies [48] suggested that genetic
variants may disturb beta-cell function and affect physiological
fasting glucose levels beneath the pathological thresholds of T2D.
In conclusion, we showed that risk alleles in GCK, GCKR,
G6PC2, and MTNR1B exert joint effects on FPG and HOMA-B.
The Asian-specific risk variants in G6PC2 may help to fine map the
causal region within the gene (or possibly the G6PC2-ABCB11
region, given the proximity and strong linkage disequilibrium
between the two genes). Concordant with previous studies, we
assumed each allele contributes equal dosage, despite minor
differences among their effect sizes. Some limitations of this study
include using adolescents as controls, which may reduce our power
as they may develop T2D later in life. This concern is partially
alleviated by obtaining similar results compared to the Chinese
and Caucasian adult cohorts (Figures S2, S3). Other studies using
adolescent cohorts also reported consistent results [44]. Our study
could be improved by using directly measured insulin data rather
than surrogate measures such as HOMA-B and HOMA-IR, and
increasing the sample size of our OGTT-based associations. Our
results could be further improved by using the PACT method
instead of FDR to correct for multiple comparisons, which
considered the correlation structure among both SNPs and
phenotypes and is less conservative [40]. Future studies in other
populations would substantiate our finding.
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Figure S3 Meta-analysis of associations of G6PC2 rs560887 and
rs16856187 with fasting plasma glucose in European and Chinese
populations, respectively.
Found at: doi:10.1371/journal.pone.0011428.s006 (0.06 MB
DOC)
Figure S4 Linkage disequilibrium for SNPs within the region
near G6PC2 and ABCB11 at chromosome 2 between 169.47 Mb
and 169.49 Mb.
Found at: doi:10.1371/journal.pone.0011428.s007 (0.12 MB
DOC)
Acknowledgments
We are grateful to all study subjects who took part in these studies. We
thank Ms. Cherry Chiu and Dr. Gary Wong for recruitment of study
subjects, and Mr. Alex Ng and Ms. Patty Tse for technical assistance. We
thank deCODE Genetics, Iceland, for help with genotyping of samples,
and the CUHK Centre for Clinical Trials and Information Technology
Services Centre for support of computing resources. Special thanks are
extended to all nursing and medical staff at the PWH Diabetes and
Endocrine Centre for their dedication and professionalism.
Author Contributions
Conceived and designed the experiments: MM WYS RCWM JCNC
MCN. Performed the experiments: VKL SG. Analyzed the data: CHTT
JSKH YW HML. Contributed reagents/materials/analysis tools: SG MM.
Wrote the paper: CHTT JSKH. Recruitment of patients: YW.
References
1. (2006) Diagnosis and classification of diabetes mellitus. Diabetes Care 29 Suppl
1: S43–48.
2. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of
diabetes mellitus and its complications. Part 1: diagnosis and classification of
diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:
539–553.
3. Shaw JE, Zimmet PZ, Hodge AM, de Courten M, Dowse GK, et al. (2000)
Impaired fasting glucose: how low should it go? Diabetes Care 23: 34–39.
4. Unwin N, Shaw J, Zimmet P, Alberti KG (2002) Impaired glucose tolerance and
impaired fasting glycaemia: the current status on definition and intervention.
Diabet Med 19: 708–723.
5. Piche ME, Arcand-Bosse JF, Despres JP, Perusse L, Lemieux S, et al. (2004)
What is a normal glucose value? Differences in indexes of plasma glucose
homeostasis in subjects with normal fasting glucose. Diabetes Care 27:
2470–2477.
6. Freeman MS, Mansfield MW, Barrett JH, Grant PJ (2002) Heritability of
features of the insulin resistance syndrome in a community-based study of
healthy families. Diabet Med 19: 994–999.
7. Li JK, Ng MC, So WY, Chiu CK, Ozaki R, et al. (2006) Phenotypic and genetic
clustering of diabetes and metabolic syndrome in Chinese families with type 2
diabetes mellitus. Diabetes Metab Res Rev 22: 46–52.
8. Zhang S, Liu X, Yu Y, Hong X, Christoffel KK, et al. (2009) Genetic and
Environmental Contributions to Phenotypic Components of Metabolic Syn-
drome: A Population-based Twin Study. Obesity (Silver Spring).
9. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, Sparso T, Holmkvist J,
et al. (2009) A variant near MTNR1B is associated with increased fasting plasma
glucose levels and type 2 diabetes risk. Nat Genet 41: 89–94.
10. Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, et al. (2009)
Variants in MTNR1B influence fasting glucose levels. Nat Genet 41: 77–81.
11. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, et al. (2008) Meta-
analysis of genome-wide association data and large-scale replication identifies
additional susceptibility loci for type 2 diabetes. Nat Genet 40: 638–645.
12. Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to
insulin resistance and type 2 diabetes. Nature 444: 840–846.
13. Issad T, Kuo M (2008) O-GlcNAc modification of transcription factors, glucose
sensing and glucotoxicity. Trends Endocrinol Metab 19: 380–389.
14. Lyssenko V, Nagorny CL, Erdos MR, Wierup N, Jonsson A, et al. (2009)
Common variant in MTNR1B associated with increased risk of type 2 diabetes
and impaired early insulin secretion. Nat Genet 41: 82–88.
15. Matschinsky F, Liang Y, Kesavan P, Wang L, Froguel P, et al. (1993)
Glucokinase as pancreatic beta cell glucose sensor and diabetes gene. J Clin
Invest 92: 2092–2098.
16. Newgard CB, Lu D, Jensen MV, Schissler J, Boucher A, et al. (2002) Stimulus/
secretion coupling factors in glucose-stimulated insulin secretion: insights gained
from a multidisciplinary approach. Diabetes 51 Suppl 3: S389–393.
17. Peschke E (2008) Melatonin, endocrine pancreas and diabetes. J Pineal Res 44:
26–40.
18. Muhlbauer E, Gross E, Labucay K, Wolgast S, Peschke E (2009) Loss of
melatonin signalling and its impact on circadian rhythms in mouse organs
regulating blood glucose. Eur J Pharmacol 606: 61–71.
19. Van Schaftingen E (1994) Short-term regulation of glucokinase. Diabetologia 37
Suppl 2: S43–47.
20. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, et al. (2007)
Genome-wide association analysis identifies loci for type 2 diabetes and
triglyceride levels. Science 316: 1331–1336.
21. Qi Q, Wu Y, Li H, Loos RJ, Hu FB, et al. (2009) Association of GCKR
rs780094, alone or in combination with GCK rs1799884, with type 2 diabetes
and related traits in a Han Chinese population. Diabetologia 52: 834–843.
22. Beer NL, Tribble ND, McCulloch LJ, Roos C, Johnson PR, et al. (2009) The
P446L variant in GCKR associated with fasting plasma glucose and triglyceride
levels exerts its effect through increased glucokinase activity in liver. Hum Mol
Genet.
23. Rose CS, Ek J, Urhammer SA, Glumer C, Borch-Johnsen K, et al. (2005) A -
30G.A polymorphism of the beta-cell-specific glucokinase promoter associates
with hyperglycemia in the general population of whites. Diabetes 54:
3026–3031.
24. Tam CH, Ma RC, So WY, Wang Y, Lam VK, et al. (2009) Interaction effect of
genetic polymorphisms in glucokinase (GCK) and glucokinase regulatory protein
(GCKR) on metabolic traits in healthy Chinese adults and adolescents. Diabetes
58: 765–769.
25. Vaxillaire M, Veslot J, Dina C, Proenca C, Cauchi S, et al. (2008) Impact of
common type 2 diabetes risk polymorphisms in the DESIR prospective study.
Diabetes 57: 244–254.
26. Froguel P, Zouali H, Vionnet N, Velho G, Vaxillaire M, et al. (1993) Familial
hyperglycemia due to mutations in glucokinase. Definition of a subtype of
diabetes mellitus. N Engl J Med 328: 697–702.
27. Wang Y, Flemming BP, Martin CC, Allen SR, Walters J, et al. (2008) Long-
range enhancers are required to maintain expression of the autoantigen islet-
specific glucose-6-phosphatase catalytic subunit-related protein in adult mouse
islets in vivo. Diabetes 57: 133–141.
28. Bouatia-Naji N, Rocheleau G, Van Lommel L, Lemaire K, Schuit F, et al.
(2008) A polymorphism within the G6PC2 gene is associated with fasting plasma
glucose levels. Science 320: 1085–1088.
29. Chen WM, Erdos MR, Jackson AU, Saxena R, Sanna S, et al. (2008) Variations
in the G6PC2/ABCB11 genomic region are associated with fasting glucose
levels. J Clin Invest 118: 2620–2628.
30. Rose CS, Grarup N, Krarup NT, Poulsen P, Wegner L, et al. (2009) A variant in
the G6PC2/ABCB11 locus is associated with increased fasting plasma glucose,
increased basal hepatic glucose production and increased insulin release after
oral and intravenous glucose loads. Diabetologia 52: 2122–2129.
31. Hu C, Zhang R, Wang C, Ma X, Fang Q, et al. (2009) A genetic variant of
G6PC2 is associated with type 2 diabetes and fasting plasma glucose level in the
Chinese population. Diabetologia 52: 451–456.
32. Reiling E, van ’t Riet E, Groenewoud MJ, Welschen LM, van Hove EC, et al.
(2009) Combined effects of single-nucleotide polymorphisms in GCK, GCKR,
G6PC2 and MTNR1B on fasting plasma glucose and type 2 diabetes risk.
Diabetologia.
33. Ng MC, Park KS, Oh B, Tam CH, Cho YM, et al. (2008) Implication of genetic
variants near TCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2,
and FTO in type 2 diabetes and obesity in 6,719 Asians. Diabetes 57:
2226–2233.
34. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985)
Homeostasis model assessment: insulin resistance and beta-cell function from
fasting plasma glucose and insulin concentrations in man. Diabetologia 28:
412–419.
35. Phillips DI, Clark PM, Hales CN, Osmond C (1994) Understanding oral glucose
tolerance: comparison of glucose or insulin measurements during the oral
glucose tolerance test with specific measurements of insulin resistance and insulin
secretion. Diabet Med 11: 286–292.
36. Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral
glucose tolerance testing: comparison with the euglycemic insulin clamp.
Diabetes Care 22: 1462–1470.
37. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007)
PLINK: a tool set for whole-genome association and population-based linkage
analyses. Am J Hum Genet 81: 559–575.
Chinese Fasting Glucose Genes
PLoS ONE | www.plosone.org 7 July 2010 | Volume 5 | Issue 7 | e1142838. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-
analysis of observational studies in epidemiology: a proposal for reporting. Meta-
analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA
283: 2008–2012.
39. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I (2001) Controlling the false
discovery rate in behavior genetics research. Behav Brain Res 125: 279–284.
40. Conneely KN, Boehnke M (2007) So Many Correlated Tests, So Little Time!
Rapid Adjustment of P Values for Multiple Correlated Tests. Am J Hum Genet
81.
41. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin
Trials 7: 177–188.
42. Purcell S, Cherny SS, Sham PC (2003) Genetic Power Calculator: design of
linkage and association genetic mapping studies of complex traits. Bioinformatics
19: 149–150.
43. Ronn T, Wen J, Yang Z, Lu B, Du Y, et al. (2009) A common variant in
MTNR1B, encoding melatonin receptor 1B, is associated with type 2 diabetes
and fasting plasma glucose in Han Chinese individuals. Diabetologia 52:
830–833.
44. Kelliny C, Ekelund U, Andersen LB, Brage S, Loos RJ, et al. (2009) Common
genetic determinants of glucose homeostasis in healthy children: the European
Youth Heart Study. Diabetes 58: 2939–2945.
45. Takeuchi F, Katsuya T, Chakrewarthy S, Yamamoto K, Fujioka A, et al.
Common variants at the GCK, GCKR, G6PC2-ABCB11 and MTNR1B loci
are associated with fasting glucose in two Asian populations. Diabetologia 53:
299–308.
46. Sparso T, Bonnefond A, Andersson E, Bouatia-Naji N, Holmkvist J, et al. (2009)
G-allele of intronic rs10830963 in MTNR1B confers increased risk of impaired
fasting glycemia and type 2 diabetes through an impaired glucose-stimulated
insulin release: studies involving 19,605 Europeans. Diabetes 58: 1450–1456.
47. Langenberg C, Pascoe L, Mari A, Tura A, Laakso M, et al. (2009) Common
genetic variation in the melatonin receptor 1B gene (MTNR1B) is associated
with decreased early-phase insulin response. Diabetologia 52: 1537–1542.
48. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, et al. (2010) New
genetic loci implicated in fasting glucose homeostasis and their impact on type 2
diabetes risk. Nat Genet 42: 105–116.
49. Fernandez-Mejia C, Vega-Allende J, Rojas-Ochoa A, Rodriguez-Dorantes M,
Romero-Navarro G, et al. (2001) Cyclic adenosine 39,59-monophosphate
increases pancreatic glucokinase activity and gene expression. Endocrinology
142: 1448–1452.
50. Grupe A, Hultgren B, Ryan A, Ma YH, Bauer M, et al. (1995) Transgenic
knockouts reveal a critical requirement for pancreatic beta cell glucokinase in
maintaining glucose homeostasis. Cell 83: 69–78.
Chinese Fasting Glucose Genes
PLoS ONE | www.plosone.org 8 July 2010 | Volume 5 | Issue 7 | e11428